Send the link below via email or IMCopy
Present to your audienceStart remote presentation
- Invited audience members will follow you as you navigate and present
- People invited to a presentation do not need a Prezi account
- This link expires 10 minutes after you close the presentation
- A maximum of 30 users can follow your presentation
- Learn more about this feature in our knowledge base article
Manchester Institute of Biotechnology 10 Year Timeline
Transcript of Manchester Institute of Biotechnology 10 Year Timeline
Professor John McCarthy
Founding Director of the MIB
Centre of Excellence in Biocatalysis, Biotransformations and Biocatalytic Manufacture
CoEBio3 was established in October 2005 in response to the need to create an organisation in the UK with academic industrial know-how to exploit the commercial opportunities of Industrial Biotechnology creating new biocatalyst-based processes to meet the changing needs of industry.
Planning begins on a new concept in life science research at UMIST
The MIB was made possible by funding from the Wellcome Trust, which provided £15 million towards the total build cost of £38 million. UMIST allocated £5.3 million from government infrastructure funds and in 2007 The Wolfson Foundation awarded the Institute £2 million for the fit out of Floor 2.
Manchester Interdisciplinary Biocentre completed
The Manchester Interdisciplinary Biocentre represented the first university-based purpose built interdisciplinary research institute of its kind in the UK.
Driving discovery through innovation
Harnessing the synergy of interdisciplinarity
Design promotes interaction
Working across boundaries - pluralistic, integrative and non-exclusive
Winner "Building of the Year"
Manchester Chamber of Commerce
Awarded £6.4M by the BBSRC and EPSRC to pioneer the development of new experimental and computational technologies in Systems Biology, and their exploitation.
It is one of six BBSRC Integrative Systems Biology Research Centres in the UK.
The Doctoral Training Centre in Systems Biology was established in 2007.
National Centre for Text Mining (NaCTeM)
First publicly funded text mining centre in the world.
Phase I (2004-2007) received £1M from JISC with contributions from EPSRC/BBSRC
Phase II (2007-2011) received £1.8M from JISC
Fully sustainable model since 2011.
From 2008-2015 NacTeM provides text mining services for Europe PubMedCentral
The Manchester Centre for Integrative Systems Biology (MCISB)
Centres of Excellence
University of Manchester Institute of Science and Technology (UMIST)
Victoria University of Manchester
Biomedical Start Up of the Year
C3 Bio-Technologies Ltd
Synthetic Biology Centre for Fine and Speciality Chemicals (SYNBIOCHEM)
The University of Manchester was awarded
from BBSRC/EPSRC to set up the Centre for Synthetic Biology of Fine and Speciality Chemicals (SYNBIOCHEM), to develop new faster, more predictable and reliable “greener” routes to fine and speciality chemicals production.
The UK is a leading centre of competence in fine and speciality chemicals
Increased uptake of biocatalysis and fermentation in the existing chemical industry
North West - home to the biggest concentration of chemicals manufacturing in the UK
UK becomes a top three producer of high value chemicals in plants
UK becomes a leading source of know how in producing commodity and intermediate chemicals through biocatalysis and fermentation
Generates more than £10bn of sales a year contributing £3bn to regional economy
Our vision is to harness the power of Synthetic Biology (SynBio) to propel chemicals and natural products production towards ’green’ and sustainable manufacturing processes.
a series of Grand Challenges from across our research themes
on advanced quantitative methods to explore specific biotechnology challenges
internationally recognised research programmes across all disciplines
positively across society, the environment and the economy.
Manchester Institute of Biotechnology
Industrial-Academia Networks in
Industrial Biotechnology and Bioenergy (NIBB)
Pooling skills from academia and business to develop research projects with the potential to overcome major challenges in the IBBE arena.
Europe’s largest public-private partnership dedicated to the development of manufacturing sustainable pharmaceuticals launched, led by MIB@UoM and pharmaceutical company GlaxoSmithKline.
The €26.4M (£21.2M) project, CHEM21, brings together six pharmaceutical companies, 13 Universities and four small to medium enterprises from across Europe. The aim is to develop sustainable biological and chemical alternatives to finite materials, such as precious metals, which are currently used as catalysts in the manufacture of medicines.
The University of Manchester’s
launched in 2015 highlighting examples of pioneering discoveries, interdisciplinary collaboration and cross-sector partnerships that are tackling some of the biggest challenges facing the planet.
Addressing global inequalities
Global challenges, Manchester solutions
26 October 2006
10 Year Anniversary Celebrations 2016/17
Symposium : That Was Then, This is Now
Celebrating 10 years of driving discovery through innovation
International Seminar Series - meet our Scientific Advisory Board
Behind the Scenes of Science
The Complex Life of Sugars Exhibition
Science Programme of events as part of ESOF 2016
To feed or not to feed? Early life nutrition and food allergy prevention
Prof. Clare Mills
Synthetic Biology and the new bio-industrial revolution
Synthetic Biology, the pathway to commercialisation
Mass Spectrometry for the masses
Prof. Perdita Barran
NATURE REVIEWS MOLECULAR CELL BIOLOGY VOLUME 5 NOVEMBER 2004
The Manchester team will work with 38 partners including, industrial stakeholders (represented by Unilever and Eurofins), patient groups representing people at risk of severe allergic reactions from Germany, UK and Ireland and a risk manager and assessor group including the UK Food Standards Agency.
World’s biggest study of food allergies gets underway
Professor Clare Mills is heading the world's biggest study of food allergy. The €9million project builds on an earlier €14.3 million research study and will involve the world’s leading experts in the UK, Europe, Australia and US.
The MIB is Europe's leading industry-interfaced biotechnology research institute. In the last 10 YEARS we have secured over
51 patents, established 8 spin-out companies, filed more than 230 new invention disclosures and 11 licenses.
Secured over >£160M funding since inception, current live grant portfolio >£85M
Over 30% of our academic staff have been awarded professorial fellowships or career development fellowships.
We are committed to training the interdisciplinary scientists of tomorrow through our EU science and training programs.
We have published over >2800 publications (>29% in top 10%) and collaborate with >70 countries.
EU Science and Training Programmes
EU FP7 Consortium Awards
There is no industry better positioned than industrial biotechnology to respond to society's grand challenges as we tackle an ageing and ever increasing population, affordable healthcare, resource efficiency, food security, climate change and energy shortages.
Transforming manufacturing through industrial biotechnology
“Improving the sustainability of our drug manufacturing processes through collaborations will not only reduce our industry’s carbon footprint but will also provide savings that can be reinvested in the development of new medicines, increased access to medicines through cost reduction and drive innovations that will simplify and transform our manufacturing paradigm.”
John Baldoni, SeniorVice-President of Platform and Technology Science, GlaxoSmithKline
Michael Barber Centre for Collaborative Mass Spectrometry
relocated to MIB 2006
In 2012 Professor Perdita Barran was appointed to the Waters Chair in Mass Spectrometry and Director of the Michael Barber Centre for Collaborative Mass Spectrometry.
"From the creation of the first commercial mass spectrometers in 1948, Manchester has been a world leader in this exciting, interdisciplinary field sharing an extraordinary heritage in both academic and commercial mass spectrometry.
Our relationship with the University in this field goes back over 40 years, and has led to global impacts in the use of mass spectrometry for pharmaceutical development, food and beverage safety, forensics, environmental monitoring, sports doping and even locally into routine diagnostic use in Manchester's hospitals".
Brian Smith, Vice President of Mass Spectrometry Business Operations
Royal Society Wolfson Research Merit Award
Profs. Sabine Flitsch (07-12), Douglas Kell (05-08), David Leys (16-20), Nigel Scrutton (09-14), Nicholas Turner (11-16)
EPSRC Advanced Fellowship
Dr. Rein Ulijn (06-11)
BBSRC Professorial Fellowship
Profs. John McCarthy (2007)
Nigel Scrutton (2006)
Wellcome Career Development Fellowship
Dr. Anna Roujenikova (06-10)
The Royal Society
Dorothy Hodgkin Fellowship
Dr. Claire Eyers (06-10)
EPSRC Life Science Interface Fellowships
Drs. Matt Baker (07-10). Sarah Hart (07-10)
Lu Shin Wong (08-11)
EPSRC Research Fellowship
Dr. Alberto Saiani (13-17)
EPSRC Established Career Fellowship
Profs. Paul Popelier (13-18)
Nigel Scrutton (12-17)
Leverhulme Trust Research Leadership Award
Drs. Rein Ulijn (07-12), Aline Miller (14-18)
The Royal Society
University Research Fellowship
Drs. David Leys (03-08) (08-11)
Nature Reviews Molecular Cell Biology
Vol 5 Nov 2004 John McCarthy
Tackling the challenges of interdisciplinary bioscience
The MIB promotes new career track research fellowships at the interface between engineering, the physical sciences and bioscience. We offer an additional 1-2 years support to top up externally funded research fellowships to enable our fellows to reach their full potential leading into independent academic careers at Manchester.
BBSRC David Phillips Fellowship
Sam Hay (10-15), Anthony Green (15-20), Neil Dixon (14-18)
EPSRC Career Acceleration Fellowship
Dr. Chris Blanford (11-16)
Royal Society University Research Fellowship
Mike Buckley (13-18)
MIB Research Fellowship Scheme launched
“Over the years our research strategy has evolved focussing on emerging areas of excellence in the wider biotechnology field. The establishment of multi-skilled interdisciplinary teams has generated unique capabilities that cannot not be realised through virtual associations and has placed us in a strong position to translate this knowledge towards biotechnological application.
Manchester Institute of Biotechnology
captures in our name our leading research activity in the many areas of biotechnology, including medical biotechnology and therapeutics, and industrial biotechnology whilst making a bold statement about the research focus and future of the Institute”.
Professor Nigel Scrutton, Director
Manchester is leading a bio-industrial revolution that will lead to applications in many sectors, including healthcare, sustainable energy, green chemistry, pharmaceuticals, novel materials and bioremediation.
Early career researchers’ perspectives on synthetic biology
Launch of MOOC on Industrial Biotechnology
Exploring the ways in which chemistry, biology and engineering principles contribute to interdisciplinary efforts within industrial biotechnology to develop innovative processes and products are that economically viable, environmentally compatible and socially responsible.
23-27 July 2016
We are committed to the pursuit of research excellence, education, knowledge transfer and discovery through innovation where our research community work towards developing new biotechnologies that will find applications in areas such as human health, the energy economy, food security, industrial transformations and the environment.
Royal Society Summer Exhibition
Professor Sabine Flitsch hosted an exhibitio n stand at the prestigious Royal Society Summer Exhibition
Visited by over 12,500 people including students, teachers, public and key decision makers and scientists.
Illustraiting how the study of carbohydrates can help improve many aspects of our lives from renewable energy and materials to generating new medicines.
'Cell Invaders' wins best game at the Games Jam.
Binding of the egg and sperm
using cell surface sugars
New drug treatments for Alzheimer's - adopting a drug repositioning strategy
Bacteria sheds light on new drug targets for cancers BRCA1 and BRCA2
GlycoBioM bringing us one step closer to understanding cancer
Degenerative disease researchers make breakthrough in bid to find treatments for Parkinson's and Huntington's
Developing technologies to produce inexpensive pharmaceuticals
Towards early disease diagnosis through technology development
Bacteria making oil
Enzymes for energy conversion
In the News
"These new networks bring together internationally competitive, cross disciplinary communities capable of undertaking innovative research that will attract further investment from the UK and abroad. "
Dr Celia Caulcott
BBSRC Executive Director, Innovation and Skills
The MIB is home to a unique multi- and inter-discplinary community of researchers trained in
committed to working across discipline boundaries.
47 Academic interdisciplinary research groups
>500 interdisciplinary researchers
A vibrant intersectorial hub
Current live grant portfolio >£85M
Spin-out company C4X Discovery (formerly Conformetrix) was created at The University of Manchester with funding from BBSRC, and is helping pharmaceutical companies speed up their drug discovery pipelines and identify potential new drugs.
C4X Discovery was valued at £31M when it floated on the London Stock Exchange in 2014
academic staff awarded professorial or career development fellowships
As a hub for EU and Industry funded programs the partnerships and relationships we have forged with other universities, government, RCUK and industry have been fundamental to our success.
"If we are to respond adequately to the major challenges of modern bioscience research in this century, we will need to develop an entirely new culture of multidisciplinary research practice and training..."
Professor John McCarthy
Founding Director (1998 - 2006)
MIB : revolutionizing modern bioscience research
Nigel Scrutton appointed Director
"MIB needs to enhance further its international profile in key areas of biotechnology including industrial biotechnology and bioenergy (IBBE) and biotechnology for healthcare. Closer interaction with industrial partners and leading international groups will drive more effective translation of MIB discovery science towards commercial exploitation".